Get the Stockscreener App
172.65
0.32%
1.155
Axsome Therapeutics Inc stock is traded at $172.65, with a volume of 556.54K.
It is up +0.32% in the last 24 hours and up +15.29% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$171.49
Open:
$173
24h Volume:
556.54K
Relative Volume:
0.98
Market Cap:
$8.69B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-26.44
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
+15.62%
1M Performance:
+15.29%
6M Performance:
+63.16%
1Y Performance:
+102.09%
1-Day Range:
$170.30
$176.00
1-Week Range:
$158.49
$184.40
52-Week Range:
$79.19
$184.40
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
172.31 | 8.65B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.16 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.22 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.06 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
802.27 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.79 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
UBS Adjusts Price Target on Axsome Therapeutics to $248 From $163, Maintains Buy Rating - marketscreener.com
Axsome Therapeutics (AXSM) Stock Analysis: Revenue Growth Soars Amid Biotech Innovations - DirectorsTalk Interviews
AXSM: HC Wainwright & Co. Raises Price Target to $200 and Mainta - GuruFocus
Stanley Laman Group Ltd. Makes New $2.13 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics - The Pharma Letter
Axsome Therapeutics Insider Sold Shares Worth $6,206,969, According to a Recent SEC Filing - marketscreener.com
Why Axsome Therapeutics (AXSM) Is Up 17.5% After Dual FDA Boosts For AXS-05 And AXS-12 – And What's Next - Yahoo Finance
Axsome Therapeutics (AXSM): Reassessing Valuation After Key FDA Milestones for AXS-05 and AXS-12 - Yahoo Finance
Axsome therapeutics director Saad sells $6.2m in shares By Investing.com - Investing.com Canada
Mark Saad Sells 37,577 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Glaukos (GKOS) - The Globe and Mail
A Comprehensive Guide To Axsome: Unlocking The Potential Of Innovative Therapeutics- - shababeek.org
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation - Finviz
Truist Securities reiterates Buy rating on Axsome Therapeutics stock By Investing.com - Investing.com Canada
Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar? - Yahoo Finance
Deutsche Bank Raises Price Target on Axsome Therapeutics to $223 From $186, Keeps Buy Rating - marketscreener.com
FDA grants Axsome’s AXS-05 sNDA priority review designation - The Pharma Letter
AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation - ts2.tech
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug - ts2.tech
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Praxis Precision Medicines (PRAX) - The Globe and Mail
Axsome Advances AXS-12 Toward NDA Filing for Narcolepsy - The Globe and Mail
Why Axsome Therapeutics Inc. stock is rated strong buyStock Buyback Announcements & Affordable Stock Picks - bollywoodhelpline.com
Axsome (AXSM) Stock; Climbs Nearly 23% After FDA Accelerates Alzheimer’s Review - CoinCentral
Moody Aldrich Partners LLC Trims Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing - ts2.tech
Axsome wins FDA priority review for Auvelity in Alzheimer’s disease agitation - MSN
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review - ts2.tech
FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12 By Investing.com - Investing.com Nigeria
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 - The Globe and Mail
Axsome Therapeutics Stock Skyrockets: What’s Next? - StocksToTrade
Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation - ts2.tech
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? - AOL.com
Key Takeaways - StocksToTrade
Axsome’s Surprising Surge: What’s Next ? - timothysykes.com
From Haiti to Wall Street to Big Pharma: Herriot Tabuteau is on a $6B mission to heal the brain - AOL.com
Axsome Therapeutics price target raised to $217 from $202 at Mizuho - TipRanks
Baird reiterates Outperform rating on Axsome Therapeutics stock By Investing.com - Investing.com Nigeria
Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing - ts2.tech
Axsome Therapeutics says AXS-12 NDA submission on track for January - TipRanks
Baird reiterates Outperform rating on Axsome Therapeutics stock - Investing.com
Axsome Therapeutics Stock Surge Analysis - timothysykes.com
Axsome Therapeutics: Late-Stage CNS Pipeline and Regulatory Tailwinds Support Buy Rating - TipRanks
Mizuho raises Axsome Therapeutics stock price target on regulatory progress - Investing.com
Axsome stock jumps on FDA priority review for Alzheimer’s agitation drug - Investing.com
Mizuho raises Axsome Therapeutics stock price target on regulatory progress By Investing.com - Investing.com UK
Pharmaceutical Stocks To Follow NowDecember 31st - MarketBeat
Mizuho Lifts Price Target on Axsome Therapeutics to $217 From $202, Keeps Outperform Rating - marketscreener.com
Oppenheimer raises Axsome Therapeutics stock price target to $220 on FDA news - Investing.com
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating - 富途牛牛
Axsome Therapeutics announces FDA acceptance, priority review of AXS-05 sNDA - TipRanks
Morgan Stanley reiterates Overweight rating on Axsome stock with $196 target - Investing.com
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Saad Mark E | Director |
Dec 31 '25 |
Option Exercise |
5.46 |
37,577 |
205,135 |
41,348 |
| Saad Mark E | Director |
Dec 31 '25 |
Sale |
165.18 |
37,577 |
6,206,969 |
10,002 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):